Amerise Biosciences Ltd: Snehjeev Ventures Stake Reaches 9.02%

Amerise Biosciences Ltd disclosed that Snehjeev Ventures Pvt Ltd and its persons acting in concert increased their aggregate holding to 9.02% on July 20, 2026. The group bought 28,000 equity shares in the open market, taking its holding from 5,934,355 shares, or 8.98%, to 5,962,355 shares.

Why did Snehjeev Ventures disclose its increased stake?

Snehjeev Ventures made the disclosure because its aggregate holding with persons acting in concert crossed the 9% level in Amerise Biosciences. The acquisition was reported under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The threshold was crossed on July 20, 2026, following the purchase of 28,000 ordinary equity shares carrying voting rights. The disclosure was submitted to BSE Limited on July 29, 2026. Such filings provide public information on changes in substantial shareholdings, without by themselves indicating a change in control or a takeover proposal.

The acquirer stated that it does not belong to the promoter or promoter group of Amerise Biosciences. The filing also recorded that the transaction involved no pledges, liens, encumbrances, warrants or convertible instruments.

Who are the persons acting in concert with Snehjeev Ventures?

The persons acting in concert named in the disclosure are Rushank SS Lunkad, Sneha Lunkad, Riddhi Lunkad and Sanjeev Lunkad. Their holdings are aggregated with Snehjeev Ventures for the purpose of the SAST disclosure.

Rushank SS Lunkad, identified as a director of Snehjeev Ventures, signed the disclosure dated July 21, 2026. The filing describes the entire reported stake as ordinary equity shares with voting rights. No conversion or exercise of securities occurred as part of the reported transaction.

The transaction increased the group's ownership by 0.04 percentage points, from 8.98% to 9.02%. Although the number of shares acquired was limited relative to the existing holding, crossing a stated threshold required the disclosure under the applicable takeover regulations.

What does the stake transaction mean for Amerise Biosciences investors?

The filing indicates a higher concentration of shares with an outside investor group, while confirming that the acquirer is not part of the promoter group. Amerise Biosciences reported promoter holding of 0.00% for the September 2026 quarter, according to the supplied shareholding information.

Investors should distinguish the disclosed acquisition from a corporate operating update. The transaction did not alter the company's diluted share or voting capital because it was a secondary-market purchase and did not involve fresh equity issuance or convertible securities.

The available company information also states that Amerise Biosciences is currently inactive and did not generate revenue. Therefore, the shareholding disclosure does not provide evidence of a change in operations, revenue generation or financial performance. It records an ownership movement by Snehjeev Ventures and its associated persons.

What other regulatory developments has Amerise Biosciences reported?

Amerise Biosciences has reported several regulatory filings during 2026, including disclosures under the SAST framework and financial-results-related filings. Its disclosure profile identifies it as an equity filer in BSE Group XT, where the Regulation 30 disclosure framework and the events listed in Schedule III of the Listing Obligations and Disclosure Requirements Regulations apply.

The company also issued an intimation regarding book closure under Regulation 42 of the Listing Obligations and Disclosure Requirements Regulations, 2015. The supplied data does not specify the book-closure dates or the corporate action linked to that intimation, so no further inference can be drawn from it.

Separately, Amerise Biosciences said its trading window for dealings in securities would close from October 1, 2026, until 48 hours after the announcement of unaudited financial results for the quarter ended September 30, 2026. This is a compliance measure under the SEBI Prohibition of Insider Trading Regulations, 2015, and should not be interpreted as a halt in exchange trading of the shares.

How does the transaction fit Amerise Biosciences' financial position?

The disclosed stake purchase occurred against a limited operating backdrop in the supplied information. Amerise Biosciences was described as inactive with no revenue generation, while historical operating-income growth figures were presented without the underlying income values or reporting periods needed to assess current performance.

The company has authorised equity share capital of 66,06,900 equity shares with a face value of ₹10 each, totalling ₹6.61 crore. The Snehjeev Ventures transaction did not change this capital structure, as the shares were acquired from the market rather than issued by the company.

For market participants, the main verified implication is the rise in the Snehjeev Ventures group's reported voting stake to 9.02%. The filing does not state the purchase price, investment value, future acquisition plan, board nomination, operational plan or any proposed change in control.

Conclusion

Snehjeev Ventures and its persons acting in concert have increased their disclosed stake in Amerise Biosciences to 9.02% through an open-market purchase of 28,000 shares. The transaction resulted in a mandatory SAST disclosure and increased outside investor concentration, but it did not change the company's share capital or establish an operational development.

The next disclosed event to monitor is Amerise Biosciences' unaudited financial-results announcement for the quarter ended September 30, 2026. The trading window is scheduled to remain closed until 48 hours after those results are announced, while any further change in the Snehjeev Ventures group's stake would be reflected through subsequent regulatory disclosures.